[en] Coronavirus disease 2019 (COVID-19) is an acute infectious disease caused by the novel
coronavirus (SARS-CoV-2) identified in 2019. The COVID-19 outbreak continues to have devastat-
ing consequences for human lives and the global economy. The B-LiFe mobile laboratory in Pied-
mont, Italy, was deployed for the surveillance of COVID-19 cases by large-scale testing of first re-
sponders. The objective was to assess the seroconversion among the regional civil protection (CP),
police, health care professionals, and volunteers. The secondary objective was to detect asympto-
matic individuals within this cohort in the light of age, sex, and residence. In this paper, we report
the results of serological testing performed by the B-LiFe mobile laboratory deployed from June 10
to July 23, 2020. The tests included whole blood finger-prick and serum sampling for detection of
SARS-CoV-2 spike receptor-binding domain (S-RBD) antibodies. The prevalence of SARS-CoV-2
antibodies was approximately 5% (294/6013). The results of the finger-prick tests and serum sample
analyses showed moderate agreement (kappa = 0.77). Furthermore, the detection rates of serum
antibodies to the SARS-CoV-2 nucleocapsid protein (NP) and S-RBD among the seroconverted in-
dividuals were positively correlated (kappa = 0.60), at least at the IgG level. Seroprevalence studies
based on serological testing for the S-RBD protein or SARS-CoV-2 NP antibodies are not sufficient
for diagnosis but might help in screening the population to be vaccinated and in determining the
duration of seroconversion.
Disciplines :
Immunology & infectious disease
Author, co-author :
Nyabi, Omar; Université Catholique de Louvain - UCL > Institut de Recherche Expérimentale et Clinique (IREC), > Center for Applied Molecular Technologies (CTMA)
Bentahir, Mostafa; Université Catholique de Louvain - UCL > Institut de Recherche Expérimentale et Clinique (IREC), > Center for Applied Molecular Technologies (CTMA)
Ambroise, Jérôme; Université Catholique de Louvain - UCL > Institut de Recherche Expérimentale et Clinique (IREC) > Center for Applied Molecular Technologies (CTMA)
Bearzatto, Bertrand; Université Catholique de Louvain - UCL > Institut de Recherche Expérimentale et Clinique (IREC) > Center for Applied Molecular Technologies (CTMA)
Chibani, Nawfal; Université Catholique de Louvain - UCL > Institut de Recherche Expérimentale et Clinique (IREC) > Center for Applied Molecular Technologies (CTMA)
Smits, Benjamin; Université Catholique de Louvain - UCL > Institut de Recherche Expérimentale et Clinique (IREC) > Center for Applied Molecular Technologies (CTMA)
Durant, Jean François; Université Catholique de Louvain - UCL > Institut de Recherche Expérimentale et Clinique (IREC) > Center for Applied Molecular Technologies (CTMA)
Vybornov, Aleksandr; Université Catholique de Louvain - UCL > Institut de Recherche Expérimentale et Clinique (IREC) > Center for Applied Molecular Technologies (CTMA)
Thellin, Olivier ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Histologie
Elmoualij, Benaïssa ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Histologie
Gala, Jean-Luc; Université Catholique de Louvain - UCL > Institut de Recherche Expérimentale et Clinique (IREC) > Center for Applied Molecular Technologies (CTMA)
Language :
English
Title :
Diagnostic Value of IgM and IgG Detection in COVID-19 Diagnosis by the Mobile Laboratory B-LiFE: A Massive Testing Strategy in the Piedmont Region
Publication date :
24 March 2021
Journal title :
International Journal of Environmental Research and Public Health
ISSN :
1660-4601
eISSN :
1661-7827
Publisher :
Multidisciplinary Digital Publishing Institute (MDPI), Basel, Switzerland
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Gautam, A.; Kaphle, K.; Shrestha, B.; Phuyal, S. Susceptibility to SARS, MERS, and COVID-19 from animal health perspective. Open Vet. J. 2020, 10, 164–177.
Quirch, M.; Lee, J.; Rehman, S. Hazards of the cytokine storm and cytokine-targeted therapy in patients with COVID-19: Review. J Med. Internet Res. 2020, 22, e20193, doi:10.2196/20193.
de Wit, E.; van Doremalen, N.; Falzarano, D.; Munster, V.J. SARS and MERS: Recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 2016, 14, 523–534, doi:10.1038/nrmicro.2016.81.
Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497–506, doi:10.1016/S0140-6736(20)30183-5.
Joyner, M.J.; Carter, R.E.; Senefeld, J.W.; Klassen, S.A.; Mills, J.R.; Johnson, P.W.; Theel, E.S.; Wiggins, C.C.; Bruno, K.A.; Klompas, A.M.; et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N. Engl. J. Med. 2021, 384, 1015–1027, doi:10.1056/NEJMoa2031893, doi:10.1056/NEJMoa2031893.
Deb, P.; Molla, M.M.A.; Rahman, K.M.S. An update to monoclonal antibody as therapeutic option against COVID-19. Biosaf. Health 2021, 10.1016/j.bsheal.2021.02.001, doi:10.1016/j.bsheal.2021.02.001.
Petersen, E.; Koopmans, M.; Go, U.; Hamer, D.H.; Petrosillo, N.; Castelli, F.; Storgaard, M.; Al Khalili, S.; Simonsen, L. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect. Dis. 2020, 20, e238–e244, doi:10.1016/S14733099(20)30484-9.
He, N.; Lu, Y.H.; Li, L.M.; Shen, H.B.; Yang, W.Z.; Feng, Z.J. Collaboration group for the emergency research project of novel coronavirus pneumonia for national natural science foundation of, C. [Epidemiological study design of asymptomatic infection of the 2019 novel coronavirus]. Zhonghua Liu Xing Bing Xue Za Zhi 2020, 41, E078, doi:10.3760/cma.j.cn112338-20200723-00975.
Kumar, M.S.; Bhatnagar, T.; Manickam, P.; Kumar, V.S.; Rade, K.; Shah, N.; Kant, S.; Babu, G.R.; Zodpey, S.; Girish Kumar, C.P.; et al. National sero-surveillance to monitor the trend of SARS-CoV-2 infection transmission in India: Protocol for communitybased surveillance. Indian J. Med. Res. 2020, 151, 419–423, doi:10.4103/ijmr.IJMR_1818_20.
Amanat, F.; Stadlbauer, D.; Strohmeier, S.; Nguyen, T.H.O.; Chromikova, V.; McMahon, M.; Jiang, K.; Asthagiri Arunkumar, G.; Jurczyszak, D.; Polanco, J.; et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv 2020, 26, 1033–1036, doi:10.1101/2020.03.17.20037713, doi:10.1101/2020.03.17.20037713.
Ul-Rahman, A.; Shabbir, M.A.B.; Aziz, M.W.; Yaqub, S.; Mehmood, A.; Raza, M.A.; Shabbir, M.Z. A comparative phylogenomic analysis of SARS-CoV-2 strains reported from non-human mammalian species and environmental samples. Mol. Biol. Rep. 2020, 47, 9207–9217, doi:10.1007/s11033-020-05879-5, doi:10.1007/s11033-020-05879-5.
Huo, J.; Le Bas, A.; Ruza, R.R.; Duyvesteyn, H.M.E.; Mikolajek, H.; Malinauskas, T.; Tan, T.K.; Rijal, P.; Dumoux, M.; Ward, P.N.; et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat. Struct. Mol. Biol. 2020, 27, 846–854, doi:10.1038/s41594-020-0469-6.
Tilocca, B.; Soggiu, A.; Sanguinetti, M.; Musella, V.; Britti, D.; Bonizzi, L.; Urbani, A.; Roncada, P. Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in taxonomically related coronaviruses. Microbes. Infect. 2020, 22, 188– 194, doi:10.1016/j.micinf.2020.04.002.
Deshpande, G.R.; Sapkal, G.N.; Tilekar, B.N.; Yadav, P.D.; Gurav, Y.; Gaikwad, S.; Kaushal, H.; Deshpande, K.S.; Kaduskar, O.; Sarkale, P.; et al. Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients. Indian J. Med. Res. 2020, 152, 82–87, doi:10.4103/ijmr.IJMR_2382_20.
Anna, F.; Goyard, S.; Lalanne, A.I.; Nevo, F.; Gransagne, M.; Souque, P.; Louis, D.; Gillon, V.; Turbiez, I.; Bidard, F.C.; et al. High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris. Eur. J Immunol. 2021, 51, 180–190, doi:10.1002/eji.202049058.
Bwire, G.M.; Majigo, M.V.; Njiro, B.J.; Mawazo, A. Detection profile of SARS-CoV-2 using RT-PCR in different types of clinical specimens: A systematic review and meta-analysis. J. Med. Virol. 2021, 93, 719–725, doi:10.1002/jmv.26349, doi:10.1002/jmv.26349.
Wang, W.; Xu, Y.; Gao, R.; Lu, R.; Han, K.; Wu, G.; Tan, W. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA 2020, 10.1001/jama.2020.3786, doi:10.1001/jama.2020.3786.
Montesinos, I.; Gruson, D.; Kabamba, B.; Dahma, H.; Van den Wijngaert, S.; Reza, S.; Carbone, V.; Vandenberg, O.; Gulbis, B.; Wolff, F.; et al. Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies. J. Clin. Virol. 2020, 128, 104413, doi:10.1016/j.jcv.2020.104413.
Corman, V.M.; Drosten, C. Authors' response: SARS-CoV-2 detection by real-time RT-PCR. Euro. Surveill. 2020, 25, 2001035, doi:10.2807/1560-7917.ES.2020.25.21.2001035.
Cassaniti, I.; Percivalle, E.; Sarasini, A.; Cambie, G.; Batisti Biffignandi, G.; Cereda, D.; Baldanti, F. Authors' response: COVID 19: How accurate are seroprevalence studies? Euro. Surveill. 2020, 25, 2001437, doi:10.2807/1560-7917.ES.2020.25.30.2001437.
Cassaniti, I.; Novazzi, F.; Giardina, F.; Salinaro, F.; Sachs, M.; Perlini, S.; Bruno, R.; Mojoli, F.; Baldanti, F.; Members of the San Matteo Pavia, C.-T.F. Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. J. Med. Virol. 2020, 92, 1724–1727, doi:10.1002/jmv.25800.
Prazuck, T.; Colin, M.; Giache, S.; Gubavu, C.; Seve, A.; Rzepecki, V.; Chevereau-Choquet, M.; Kiani, C.; Rodot, V.; Lionnet, E.; et al. Evaluation of performance of two SARS-CoV-2 Rapid IgM-IgG combined antibody tests on capillary whole blood samples from the fingertip. PLoS ONE 2020, 15, e0237694, doi:10.1371/journal.pone.0237694.
Tomasik, P.; Krotki, F.; Jonca, M.; Anyszek, T. Rapid point-of-care antibody cassette tests for severe acute respiratory syndrome coronavirus 2: Practical considerations. Pol. Arch. Intern. Med. 2020, 130, 459–462, doi:10.20452/pamw.15311.
Glasgow, A.; Glasgow, J.; Limonta, D.; Solomon, P.; Lui, I.; Zhang, Y.; Nix, M.A.; Rettko, N.J.; Zha, S.; Yamin, R.; et al. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Proc. Natl. Acad. Sci. USA 2020, 45, 28046–28055. doi:10.1073/pnas.2016093117.
Datta, P.K.; Liu, F.; Fischer, T.; Rappaport, J.; Qin, X. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics 2020, 10, 7448–7464, doi:10.7150/thno.48076.
Ding, S.; Laumaea, A.; Gasser, R.; Medjahed, H.; Pancera, M.; Stamatatos, L.; McGuire, A.; Bazin, R.; Finzi, A. Antibody binding to SARS-CoV-2 S glycoprotein correlates with, but does not predict neutralization. bioRxiv 2020, doi:10.1101/2020.09.08.287482, doi:10.1101/2020.09.08.287482.
Yang, R.; Lan, J.; Huang, B.; A, R.; Lu, M.; Wang, W.; Wang, W.; Li, W.; Deng, Y.; Wong, G.; et al. Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections. EBioMedicine 2020, 58, 102890, doi:10.1016/j.ebiom.2020.102890.
Tan, C.W.; Chia, W.N.; Qin, X.; Liu, P.; Chen, M.I.; Tiu, C.; Hu, Z.; Chen, V.C.; Young, B.E.; Sia, W.R.; et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat. Biotechnol. 2020, 38, 1073–1078, doi:10.1038/s41587-020-0631-z.
Liu, L.; Wang, P.; Nair, M.S.; Yu, J.; Rapp, M.; Wang, Q.; Luo, Y.; Chan, J.F.; Sahi, V.; Figueroa, A.; et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 2020, 584, 450–456, doi:10.1038/s41586-020-2571-7.
Zost, S.J.; Gilchuk, P.; Case, J.B.; Binshtein, E.; Chen, R.E.; Nkolola, J.P.; Schafer, A.; Reidy, J.X.; Trivette, A.; Nargi, R.S.; et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 2020, 584, 443–449, doi:10.1038/s41586-0202548-6.
McAndrews, K.M.; Dowlatshahi, D.P.; Dai, J.; Becker, L.M.; Hensel, J.; Snowden, L.M.; Leveille, J.M.; Brunner, M.R.; Holden, K.W.; Hopkins, N.S.; et al. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight 2020, 5, e142386, doi:10.1172/jci.insight.142386.
Du, S.; Cao, Y.; Zhu, Q.; Yu, P.; Qi, F.; Wang, G.; Du, X.; Bao, L.; Deng, W.; Zhu, H.; et al. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. Cell 2020, 183, 1013–1023.e13, doi:10.1016/j.cell.2020.09.035, doi:10.1016/j.cell.2020.09.035.
Callow, K.A.; Parry, H.F.; Sergeant, M.; Tyrrell, D.A. The time course of the immune response to experimental coronavirus infection of man. Epidemiol. Infect. 1990, 105, 435–446, doi:10.1017/s0950268800048019.
Reed, S.E. The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers: Evidence of heterogeneity among 229E-related strains. J. Med. Virol. 1984, 13, 179–192, doi:10.1002/jmv.1890130208.
Sharp, T.M.; Fischer, M.; Munoz-Jordan, J.L.; Paz-Bailey, G.; Staples, J.E.; Gregory, C.J.; Waterman, S.H. Dengue and Zika Virus Diagnostic Testing for Patients with a Clinically Compatible Illness and Risk for Infection with Both Viruses. MMWR Recomm. Rep. 2019, 68, 1–10, doi:10.15585/mmwr.rr6801a1.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
